Youngseok Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Youngseok Lee has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bokyung Ahn
Department of pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
3 shared publications - Chul Hwan Kim
Department of Pathology, Korea University Anam Hospital, Seoul, Republic of Korea
3 shared publications - Eojin Kim
Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
3 shared publications - Harim Oh
Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
3 shared publications - Jeong Hyeon Lee
Department of Pathology, Korea University Anam Hospital, Seoul 02841, Republic of Korea
3 shared publications - Yang-Seok Chae
Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2020
- Published by XMLink in Investigative and Clinical Urology
- Vol. 61 (2) , 166-172
BRCA1-associated protein 1 expression and prognostic role in prostate adenocarcinoma
As prostate cancer (PCa) is the second most commonly diagnosed cancer worldwide, finding novel markers for prognosis is crucial. BRCA1-associated protein 1 (BAP-1), a nuclear-localized deubiquitinating enzyme, has been reported in several human cancers. However, its prognostic role in PCa remains unknown. Herein, we assessed the prognostic and clinicopathologic significance of BAP-1 in PCa. Seventy surgical specimens from radical prostatectomy cases were examined. Two cores per case were selected for construction of tissue microarrays (TMAs). After the exclusion of two cases because of tissue sparsity, BAP-1 immunohistochemical expression was evaluated in 68 cases of formalin-fixed, paraffin-embedded TMA tissue blocks. The immunohistochemical stain was scored according to proportion of nuclear staining: negative (<10% of tumor cells) or positive (≥10% of tumor cells). BAP-1 expression was negative in 30 cases (44.1%) and positive in 38 cases (55.9%). Positive BAP-1 expression was more common in pT3b disease than in pT2 (p=0.038). A high preoperative prostate-specific antigen level was correlated with BAP-1 expression (p=0.014). Age, lymphovascular invasion, perineural invasion, and grade group were not significantly correlated with BAP-1 expression. Patients with positive BAP-1 expression showed significantly shorter disease-free survival (p=0.013). Additionally, BAP-1 was an independent prognostic factor of PCa (p=0.035; hazard ratio, 9.277; 95% confidence interval, 1.165-73.892). Our study findings showed an association of BAP-1 expression with poor PCa prognosis and suggest a potential role for BAP-1 as a prognostic biomarker for PCa.
- 1 January 2020
- Published by XMLink in Investigative and Clinical Urology
- Vol. 61 (2) , 166-172
Open AccessBRCA1-associated protein 1 expression and prognostic role in prostate adenocarcinoma
As prostate cancer (PCa) is the second most commonly diagnosed cancer worldwide, finding novel markers for prognosis is crucial. BRCA1-associated protein 1 (BAP-1), a nuclear-localized deubiquitinating enzyme, has been reported in several human cancers. However, its prognostic role in PCa remains unknown. Herein, we assessed the prognostic and clinicopathologic significance of BAP-1 in PCa. Seventy surgical specimens from radical prostatectomy cases were examined. Two cores per case were selected for construction of tissue microarrays (TMAs). After the exclusion of two cases because of tissue sparsity, BAP-1 immunohistochemical expression was evaluated in 68 cases of formalin-fixed, paraffin-embedded TMA tissue blocks. The immunohistochemical stain was scored according to proportion of nuclear staining: negative (<10% of tumor cells) or positive (≥10% of tumor cells). BAP-1 expression was negative in 30 cases (44.1%) and positive in 38 cases (55.9%). Positive BAP-1 expression was more common in pT3b disease than in pT2 (p=0.038). A high preoperative prostate-specific antigen level was correlated with BAP-1 expression (p=0.014). Age, lymphovascular invasion, perineural invasion, and grade group were not significantly correlated with BAP-1 expression. Patients with positive BAP-1 expression showed significantly shorter disease-free survival (p=0.013). Additionally, BAP-1 was an independent prognostic factor of PCa (p=0.035; hazard ratio, 9.277; 95% confidence interval, 1.165-73.892). Our study findings showed an association of BAP-1 expression with poor PCa prognosis and suggest a potential role for BAP-1 as a prognostic biomarker for PCa.
- Open Access
- 15 November 2019
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 53 (6) , 403-406
Adenocarcinoma Arising in an Ectopic Hamartomatous Thymoma with HER2 Overexpression
- 15 November 2019
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 53 (6) , 403-406
Open AccessAdenocarcinoma Arising in an Ectopic Hamartomatous Thymoma with HER2 Overexpression
- Open Access
- 15 September 2019
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 53 (5) , 337-340
Human Papillomavirus–Related Multiphenotypic Sinonasal Carcinoma with Late Recurrence
- 15 September 2019
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 53 (5) , 337-340
Open AccessHuman Papillomavirus–Related Multiphenotypic Sinonasal Carcinoma with Late Recurrence